eHealth SaaS company Respiri Limited (ASX:RSH) has formed a Medical Advisory Board (MAB) with leading US Key Opinion Leaders (KOL) who will help forge the company’s respiratory clinical and product development strategies and guidance on further advancing wheezo Remote Patient Monitoring (RPM) program as part of standard patient respiratory care.
The MAB will be key in supporting the Respiri’s expansion in the US by enhancing wheezo RPM healthcare utility, investigate clinical applications for the new product pipeline and provide strategic counsel and recommendations for the company’s US-centric plans including the introduction of key institutions.
The founding MAB members comprise a wealth of experience and knowledge and a diverse skill set spanning clinical pulmonology, scientific and clinical expertise and commercial medical device development and commercialisation.
William Krimsky will serve as the MAB’s first Chair and is a highly respected expert in interventional pulmonology and in the use of electromagnetic navigation bronchoscopy for the diagnosis and treatment of lung disease. He has developed innovative techniques to treat diseases of the chest, and he travels nationally and internationally to teach these techniques. He also is medical director of clinical research at Pulmonary and Critical Care Associates of Baltimore. Dr. Krimsky specialises in robotic surgery and innovative treatments for lung cancer.
Over the course of his career, Dr Krimsky has been lead investigator for several national clinical trials. He has received several awards for his work, including recognition by the New England Respiratory Research Competition and Awards Program for Excellence in Research in Respiratory Medicine. He is board certified in internal medicine, pulmonary disease, and critical care medicine, and he has specialty certification in interventional pulmonology. Dr Krimsky is a fellow of the American College of Chest Physicians and is an active member of several professional societies, including the American College of Chest Physicians, the Society of Critical Care Medicine, and the American Thoracic Society. During his career, he has been invited to speak at more than 50 congresses, events and other medical forums. In addition to his work in the United States, Dr Krimsky has travelled to teach navigational bronchoscopy to physicians in China.
The newly appointed Medical Advisory Board members are:
Professor Gerard J. Criner, MD, FACP, FACCP Chair and Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University.
Ass. Professor Stephen Selinger, MD, is a graduate of the Johns Hopkins University School of Medicine. He is an assistant professor at Georgetown University Medical Center, as well as a clinical instructor at Johns Hopkins University. Dr. Selinger is the Chief Medical Officer for Luminis Health Anne Arundel Medical Center.
Dr. Jonathan Hovda, M.D, graduated from Medical School at the University of Minnesota, where he simultaneously also received a Master of Business Administration degree from the Carlson School of Management.
We are delighted to welcome such a high calibre team of experts that add another level of sophistication to our strategy as we continue to execute our US plans. I am looking forward to working with them and learning much from them,” Respiri CEO, Marjan Mikel, said.
